期刊
JOURNAL OF INTERNAL MEDICINE
卷 291, 期 2, 页码 181-196出版社
WILEY
DOI: 10.1111/joim.13431
关键词
antidoping; athletics; doping; medical history; Olympics; performance-enhancing drugs; toxicity; toxicology
This article discusses the prohibition of performance-enhancing drugs (PEDs) in fair play rules and WADA's efforts to prevent PED use during the Olympic Games. It also reviews the characteristics and toxicities of different PED classes, emphasizing the importance for healthcare providers to be aware of PEDs and their risks, as they may encounter patients using PEDs.
The rules of fair play in sport generally prohibit the use of performance-enhancing drugs (PEDs). The World Anti-Doping Agency (WADA) oversees global antidoping regulations and testing for elite athletes participating in Olympic sports. Efforts to enforce antidoping policies are complicated by the diverse and evolving compounds and strategies employed by athletes to gain a competitive edge. Now between the uniquely proximate 2021 Tokyo and 2022 Beijing Olympic Games, we discuss WADA's efforts to prevent PED use during the modern Olympic Games. Then, we review the major PED classes with a focus on pathophysiology, complexities of antidoping testing, and relevant toxicities. Providers from diverse practice environments are likely to care for patients using PEDs for a variety of reasons and levels of sport; these providers should be aware of common PED classes and their risks.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据